Mersana Therapeutics

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Mersana Therapeutics excels in 2022, poised for oncology innovation

Mersana Therapeutics demonstrated strong performance, financial stability, and clinical progress in 2022, positioning themselves as a key player in oncology drug development.
While facing challenges in regulatory considerations and competitive dynamics, the company's strategic collaborations and pipeline advancements offer promising opportunities for future growth.
Investors should monitor Mersana's upcoming milestones, including data reporting and trial progress, as indicators of their potential for continued success and innovation.

Mersana Therapeutics progresses in Q1 with strong financials and clinical trials

Mersana Therapeutics is on track for a pivotal year with strong financials, progress in clinical trials, and plans for potential BLA submission. Challenges include diagnostic testing bottlenecks and patient pre-treatment impact on response rates. Opportunities exist in data presentations, partnerships, and subgroup analysis for improved outcomes.

Mersana Therapeutics reports improved Q3 performance and strategic partnerships

Mersana Therapeutics demonstrated improved financial performance, strong partnerships, and a focus on innovative ADC candidates. While facing challenges with clinical setbacks, the company's strategic restructuring and promising pipeline indicate opportunities for growth and success in the ADC market.

Mersana Therapeutics shows financial improvement and pipeline promise in Q1

Mersana Therapeutics demonstrated improved financial performance in Q1 2024 with reduced expenses and a lower net loss compared to the previous year.
Strengths in ADC platform advancements and promising lead candidates position Mersana well for future growth and innovation.
Challenges in clarifying key strategies and managing expenses underscore areas for improvement, while opportunities in expansion and partnerships offer avenues for advancement.

Mersana Therapeutics reports strong Q2 progress amidst financial challenges

Mersana Therapeutics demonstrated strong progress in Q2 2024 with promising clinical data for XMT-1660 and XMT-2056 ADC candidates, despite reporting a net loss.
The company's focus on optimizing dosing schedules, exploring biomarkers, and addressing resistance mechanisms underscores a commitment to advancing its pipeline.
Analysts' interest in patient responses, dosing schedules, and expansion plans highlights the market's anticipation of Mersana's future growth and innovation in the ADC space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present an analysis based on the June 10th, 2021 data cut from the expansion cohort of the Company's Phase 1 trial of upifitamab rilsodotin (UpRi) at the upcoming Society of Gynecologic Oncology Annual Meeting on Women's Cancer being held from March 18-21, 2022 in Phoenix, Arizona.

Mersana Therapeutics to Present an Analysis from the Expansion Cohort of the Phase 1 Trial of Upifitamab Rilsodotin at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the Company will participate in a virtual panel presentation at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 12:50 p.m. ET.

Mersana Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q4 2021 Results - Earnings Call Transcript

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1.49% and 10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2021.

Mersana Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Mersana Therapeutics (MRSN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Mersana Therapeutics (MRSN) This Earnings Season?

Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Mersana Therapeutics, Inc. (MRSN) to Report a Decline in Earnings: What to Look Out for

Johnson & Johnson

Mersana Therapeutics Inc MRSN has announced a research collaboration and license agreement with Janssen Biotech Inc, a unit of Johnson & Johnson JNJ, to discover antibody-drug conjugates (ADCs) for three targets. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Janssen Inks Over $1B Pact For Mersana's ADC Technology In Three targets

UPLIFT, a single-arm registrational trial of UpRi in platinum-resistant ovarian cancer, expected to complete enrollment in Q3 2022

Mersana Therapeutics Announces 2022 Strategic Priorities and Milestones

Synaffix B.V. has expanded its license agreement with Mersana Therapeutics Inc (NASDAQ: MRSN) for antibody-drug conjugates (ADCs) targeting cancers.

Mersana Therapeutics, Synaffix Expand Cancer Pact To Potential Value Exceeding $1B

CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the Company's management team will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021, at 2:40 p.m. ET.

Mersana Therapeutics to Participate in the Upcoming 4th Annual Evercore ISI HealthCONx Conference

Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q3 2021 Results - Earnings Call Transcript

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -8.62% and 10.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported financial results for the third quarter ended September 30, 2021 and provided a business update.

Mersana Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

Earnings Preview: Mersana Therapeutics, Inc. (MRSN) Q3 Earnings Expected to Decline

CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the grant of an inducement award to the newly appointed Senior Vice President Strategic Product Planning & Program Leadership, Mohan Bala, Ph.D. In connection with the appointment, the Compensation Committee of the Board of Directors of Mersana Therapeutics approved a stock option grant to Dr. Bala as an inducement material to Dr. Bala entering into employment with Mersana Therapeutics, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option grant provides for the purchase of up to 112,500 shares of Mersana Therapeutics common stock, at a price of $8.63 per share, the closing price per share of Mersana Therapeutics common stock on the date of grant, and vests over four years, with 25% of the shares vesting on the first anniversary of the Dr. Bala's employment start date, and the remainder vesting in equal quarterly installments over the following three years, subject to Dr. Bala's continued employment with Mersana Therapeutics through such applicable vesting dates.

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mersana Therapeutics Inc (NASDAQ: MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual International Conference.

Mersana Highlights New Preclinical Data For XMT-2056 Cancer Settings

CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) --  Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that XMT-2056, its first Immunosynthen STING-agonist ADC candidate, targets a novel epitope of human epidermal growth factor receptor 2 (HER2) and presented new preclinical data during a plenary session at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (Triple Meeting).

Mersana Therapeutics Announces Target and Presents New Preclinical Data for XMT-2056, First Immunosynthen STING-Agonist ADC, at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will disclose the target and present new preclinical data for XMT-2056, its first Immunosynthen STING-agonist ADC candidate, in a plenary session at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.

Mersana Therapeutics to Announce Target and Present New Preclinical Data for XMT-2056 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Mersana Therapeutics Inc (NASDAQ: MRSN) stock is moving lower during the market trading session. Investors are reacting to interim data from the ovarian cancer Phase 1 trial evaluating Upifitamab Rilsodotin (UpRi, previously XMT-1536).

Why Are Mersana Therapeutics Shares Trading Lower On Friday?

Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported financial results for the second quarter ended June 30, 2021 and provided a business update.

Mersana Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Friday, August 6, 2021 at 8:00 a.m. ET to report financial results for the second quarter ended June 30, 2021 and provide business updates.

Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2021 Financial Results and Business Updates

UPGRADE umbrella study designed to evaluate UpRi in combination with other therapies, starting with carboplatin UPGRADE umbrella study designed to evaluate UpRi in combination with other therapies, starting with carboplatin

Mersana Therapeutics Announces Initiation of the UPGRADE Phase 1 Platinum Combination Cohort for UpRi in Platinum-Sensitive Ovarian Cancer

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing antibody-drug conjugates for oncological indications.

News for Mersana Therapeutics Stock (MRSN)